Considerations into pharmacogenomics of COVID-19 pharmacotherapy: hope, hype and reality
Yükleniyor...
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Academic Press
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
COVID-19 medicines, such as molnupiravir are beginning to emerge for public health and clinical practice. On the other hand, drugs display marked variability in their efficacy and safety. Hence, COVID-19 medicines, as with all drugs, will be subject to the age-old maxim “one size prescription does not fit all”. In this context, pharmacogenomics is the study of genome-by-drug interactions and offers insights on mechanisms of patient-to-patient and between-population variations in drug efficacy and safety. Pharmacogenomics information is crucial to tailoring the patients' prescriptions to achieve COVID-19 preventive and therapeutic interventions that take into account the host biology, patients’ genome, and variable environmental exposures that collectively influence drug efficacy and safety. This expert review critically evaluates and summarizes the pharmacogenomics and personalized medicine aspects of the emerging COVID-19 drugs, and other selected drug interventions deployed to date. Here, we aim to sort out the hope, hype, and reality and suggest that there are veritable prospects to advance COVID-19 medicines for public health benefits, provided that pharmacogenomics is considered and implemented adequately. Pharmacogenomics is an integral part of rational and evidence-based medical practice. Scientists, health care professionals, pharmacists, pharmacovigilance practitioners, and importantly, patients stand to benefit by expanding the current pandemic response toolbox by the science of pharmacogenomics, and its applications in COVID-19 medicines and clinical trials.
Açıklama
Anahtar Kelimeler
Clinical Trials, COVID-19, Molnupiravir, Personalized Medicine, Pharmacogenomics
Kaynak
Pulmonary Pharmacology and Therapeutics
WoS Q Değeri
Q3
Scopus Q Değeri
N/A
Cilt
77
Sayı
Künye
AL-Taie, A., Büyük, A. Ş., & Sardas, S. (2022). Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality. Pulmonary Pharmacology and Therapeutics, 77 doi:10.1016/j.pupt.2022.102172
